Nobivac Canine 1-DAPPv+Cv

Information

Nobivac® Canine 1-DAPPv+Cv is a canine Distemper-Adenovirus Type 2-Coronavirus-Parainfluenza-Parvovirus Vaccine, Modified Live Virus. Nobivac® Canine 1-DAPPv+Cv is Nobivac® Canine 1-DAPPv just with a new name.

Features
Features & Benefits
* High antigenic mass (titer), low passage parvovirus vaccine.
* Canine vaccine containing parvovirus type 2b, the most prevalent field strain of parvovirus.
* Canine parvovirus type 2b protects against all field strains currently seen.
* Overrides maternal antibodies in young puppies. Primary vaccination may begin as early as 6 weeks. Last dose may be given at 12 weeks of age.
* No reversion to virulence.
* Onderstepoort-type distemper strain, proven efficacious for over 50 years.
* Lyophilized L. canicola and L. icterohaemorrhagiae provide broad protection with added stability and convenience

NOBIVAC^® CANINE 1-DAPPv + Cv

Intervet/Merck Animal Health

CANINE DISTEMPER-ADENOVIRUS TYPE 2-CORONAVIRUS-PARAINFLUENZA-PARVOVIRUS VACCINE Modified Live And Killed Virus

FOR ANIMAL USE ONLY

IN THE ABSENCE OF A VETERINARIAN-CLIENT-PATIENT RELATIONSHIP, FEDERAL REGULATIONS PROHIBIT THE RELABELING, REPACKAGING, RESALE OR REDISTRIBUTION OF THE INDIVIDUAL CONTENTS OF THIS PACKAGE.

THIMEROSAL FREE

PRODUCT DESCRIPTION: Nobivac^® Canine 1-DAPPv+Cv vaccine is a combination vaccine that unites the benefits of Nobivac^® Canine 1-DAPPv and Nobivac^® Canine 1-Cv in one vaccination.

INDICATIONS: This product has been shown to be effective for vaccination of healthy dogs 6 weeks of age or older against canine distemper virus, canine adenovirus type 1 (hepatitis), canine adenovirus type 2 (respiratory disease), canine parainfluenza virus, canine parvovirus and canine coronavirus. Duration of Immunity has not been established. To review efficacy and safety data, go to productdata.aphis.usda.gov.

Data indicate the development of corneal opacity is not associated with the use of this product.

DOSAGE AND ADMINISTRATION: Shake the Nobivac Canine 1-Cv vial and transfer its contents to the Nobivac Canine 1-DAPPv vial aseptically. Mix gently until dissolved. Inject one dose (1mL) subcutaneously or intramuscularly. The initial dose may be given at 6 weeks of age or older. Repeat dose 2 to 4 weeks later. Two doses are required for primary immunization.

The presence of maternal antibodies is known to interfere with the development of active immunity in dogs and additional boosters will be required in most young animals. Historically, annual revaccination has been recommended for this product. The need for this booster has not been established. For more information on revaccination frequency, in general or in the face of maternal antibody, consult your veterinarian or the manufacturer.

PRECAUTIONS:

• Store at 2° - 8°C (35°-46°F).

• Do not freeze.

• Use new, non-chemically sterilized needles and syringes.

• Do not mix with other products, except as specified on the label.

• Inactivate unused contents before disposal.

• In case of human exposure, contact a physician.

WARNINGS:

• Contains gentamicin as a preservative.

• Vaccinate only healthy, non-parasitized dogs.

• Do not vaccinate pregnant bitches.

• The use of a biological product may produce anaphylaxis and/or other inflammatory immune-mediated hypersensitivity reactions. Antidote: Epinephrine, corticosteroids, and antihistamines may all be indicated depending on the nature and severity of the reaction.

• The age at which maternal antibody for canine parvovirus no longer interferes with the development of active immunity varies according to the bitch’s titer and quantity of colostral antibodies absorbed by the puppy.

Intervet Inc. d/b/a Merck Animal Health

Omaha, NE 68103 USA

VLN 165A/PCN 1599.20

1 800 224-5318 (USA)

1 866 683-7838 (Canada)

For patent information:

http://www.merck.com/product/patent/home.html

	Code
25x1 DOSE	065289	314677-03

CPN: 1047083.7

Directions

More Information
Directions	Dosage: Shake the Nobivac^® Canine 1-Cv vial and transfer its contents to the Nobivac^® Canine 1-DAPPv vial aseptically. Mix gently until dissolved. Use entire contents immediately after rehydration. Vaccinate with 1 ml subcutaneously or intramuscularly. The initial dose may be given at 6 weeks of age or older. Repeat at 2 to 4 week intervals until the dog is 12 weeks of age. A minimum of two doses is required for primary immunization. Annual revaccination with one dose is recommended. Warnings: Contains gentamicin as a preservatives Vaccinate only healthy, non-parasitized dogs Do not vaccinate pregnant bitches The use of a biological product may produce anaphylaxis and/or other inflammatory immune-mediated hypersensitivity reactions. Antidote: Epinephrine, corticosteroids, and antihistamines may all be indicated depending on the nature and severity of the reaction. The age at which material antibody for canine Parvovirus no longer interferes with the development of active immunity varies according to the bitch's titer and quantity of colostral antibodies absorbed by the puppy.